Johnson & Johnson


Johnson & Johnson initiates spin-off and IPO of Kenvue division (Frenadol, Nicorette, Neutrogena or Listerine), valued at up to $43 billion

Banca March | The healthcare giant has launched the spin-off and IPO of its consumer division – with products such as Frenadol, Nicorette, Neutrogena and Listerine – which it will call Kenvue and which it has valued at up to $43 billion. With this placement, which will happen within a few weeks, J&J plans to sell more than 151 million Kenvue shares at a price of between $20 and $23…